LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta” or the “Company”) (Nasdaq: MNTA) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Momenta shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
On February 17, 2017, Momenta revealed that a contracted Pfizer facility used to manufacture the Company's Glatopa product was sent a warning letter from the U.S. Food and Drug Administration ("FDA").
Momenta's Abbreviated New Drug Application for its Glatopa 40 mg product candidate is under regulatory review, and under FDA policy, final approval is dependent on the proper outcome of the compliance observations at the Pfizer manufacturing facility.
On February 20, 2017, a Leerink Capital Partners LLC analyst stated that the FDA warning letter raises concerns for the Company, as manufacturing warning letters can take years to fix, and that a lengthy delay could lessen Momenta's market opportunity for Glatopa.
When this information was revealed to investors, the value of Momenta fell, causing investors harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.